Literature DB >> 19271173

Clinical observation on the treatment of male neoplastic anemia with Yixuesheng capsule combined with recombination human erythropoietin.

Zhi Cheng1, Jia-Li Wu, Jun-Fa Chen.   

Abstract

OBJECTIVE: To explore the efficacy and mechanism of Yixuesheng capsule (, YXS) combined with recombination human erythropoietin (RHE) in treating male neoplastic anemia (NA).
METHODS: Sixty-five patients were randomized into two groups, the 33 patients in the treated group treated with a combined therapy of YXS and RHE, and the 32 in the control group treated with RHE alone, all for 12 weeks. Related clinical indexes, including hemoglobin (Hgb), red blood cell (RBC), hematocrit (HMC), testosterone (T), estradiol (E(2)) and prolactin (PRL), were measured before and after treatment.)
RESULTS: After treatment, Hgb in the treated group and the control group was 108+/-5 g/L and 104+/-8 g/L respectively, showing marked improvement as compared with that before treatment (P<0.01), and the improvement in the former was more significant than that in the latter (P<0.05). Further, the level of T was also increased in the treated group after treatment (P<0.05), and showed a significant difference from that of the control group (P<0.05).
CONCLUSIONS: YXS capsule combined with RHE shows a better therapeutic effect in treating NA than that of RHE alone, and the effect might be through stimulation by YXS of erythropoiesis which could promote the secretion of testosterone.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19271173     DOI: 10.1007/s11655-009-0063-3

Source DB:  PubMed          Journal:  Chin J Integr Med        ISSN: 1672-0415            Impact factor:   1.978


  7 in total

Review 1.  Progress in understanding the pathogenesis of the anemia of chronic disease.

Authors:  R T Means; S B Krantz
Journal:  Blood       Date:  1992-10-01       Impact factor: 22.113

2.  Role of cytokines in the pathogenesis of anemia of chronic disease in rheumatoid arthritis.

Authors:  P V Voulgari; G Kolios; G K Papadopoulos; A Katsaraki; K Seferiadis; A A Drosos
Journal:  Clin Immunol       Date:  1999-08       Impact factor: 3.969

Review 3.  Role of iron in optimizing responses of anemic cancer patients to erythropoietin.

Authors:  J Glaspy; I Cavill
Journal:  Oncology (Williston Park)       Date:  1999-04       Impact factor: 2.990

4.  Clinical evaluation of once-weekly dosing of epoetin alfa in chemotherapy patients: improvements in hemoglobin and quality of life are similar to three-times-weekly dosing.

Authors:  J L Gabrilove; C S Cleeland; R B Livingston; B Sarokhan; E Winer; L H Einhorn
Journal:  J Clin Oncol       Date:  2001-06-01       Impact factor: 44.544

5.  Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial.

Authors:  T J Littlewood; E Bajetta; J W Nortier; E Vercammen; B Rapoport
Journal:  J Clin Oncol       Date:  2001-06-01       Impact factor: 44.544

Review 6.  Molecular biology of erythropoietin.

Authors:  Wolfgang Jelkmann
Journal:  Intern Med       Date:  2004-08       Impact factor: 1.271

7.  Anemia of cancer patients: patient selection and patient stratification for epoetin treatment.

Authors:  H Ludwig; E Fritz
Journal:  Semin Oncol       Date:  1998-06       Impact factor: 4.929

  7 in total
  1 in total

Review 1.  Erythropoietin or darbepoetin for patients with cancer.

Authors:  Thomy Tonia; Annette Mettler; Nadège Robert; Guido Schwarzer; Jerome Seidenfeld; Olaf Weingart; Chris Hyde; Andreas Engert; Julia Bohlius
Journal:  Cochrane Database Syst Rev       Date:  2012-12-12
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.